- /
- Supported exchanges
- / US
- / BSX.NYSE
Boston Scientific Corp (BSX NYSE) stock market data APIs
Boston Scientific Corp Financial Data Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Boston Scientific Corp (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Boston Scientific Corp data using free add-ons & libraries
Get Boston Scientific Corp Fundamental Data
Boston Scientific Corp Fundamental data includes:
- Net Revenue: 20 996 M
- EBITDA: 5 711 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-29
- EPS/Forecast: 0.83
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Boston Scientific Corp News
New
Moderna, Illumina lead healthcare gains in September as medtech drags
[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund (XLV ...
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
Boston Scientific (BSX) closed at $42.60 in the latest trading session, marking a -1.46% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.73% for the day. Els...
Can ISRG Offset China Weakness With Expansion in India and Japan?
Intuitive Surgical's ISRG geographical growth story is becoming increasingly diversified, with strong momentum in India and improving conditions in Japan helping counterbalance challenges in China. In...
2 Oversold Stocks Primed to Rebound and 1 We Find Risky
2 Oversold Stocks Primed to Rebound and 1 We Find Risky The past year hasn't been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.